Company: QTIWW
Filing Date: 2025-11-03
Form Type: S-1
Source: 0001628280-25-048373
Chunk: 372

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-11-03
Form: S-1
Chunk 372
---
 loss. As a result of Dr. Klock's retirement on December 31, 2024, the Space and Equipment Sublease Agreement was terminated.

Deferred Revenue

In July 2023, an order was placed and a downpayment of $ 200,000was made for a breast imaging system by 303 Development Corporation (the “Foundation”). The executive director of the Foundation is a current investor and a was a previous board member of the Company. In December 2023, an additional $ 100,000was paid towards the purchase. In June 2024, the Company cancelled this order and refunded the full deposit of $ 300,000to the related party. As of December 31, 2024 and 2023, the Company had a deferred revenue balance of zeroand $ 300,000, respectively, related to this order.

#### 16. Segment Information
The Company has oneoperating and reportable segment, which is engaged in the development and commercialization of the Company’s QT Breast Scanner. The Company’s Chief Executive Officer has been determined to be the chief operating decision maker (“CODM”) in accordance with the authoritative guidance on segment reporting. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 1). The CODM assesses performance, makes operating decisions and decides how to allocate resources based on net loss that is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.

The following table presents information about reported segment revenue, significant segment expenses, and segment net loss for the years ended December 31, 2024 and 2023:

|                                              |     | Year Ended December 31, |       2024 |     |   |       2023 |
|:---------------------------------------------|:----|:------------------------|-----------:|:----|:--|-----------:|
| Revenue                                      |     | $                       |  4,878,665 |     | $ |     40,355 |
| Less:                                        |     |                         |            |     |   |            |
| Cost of revenue                              |     |                         |  2,238,820 |     |   |    134,988 |
| Research and development(1)                  |     |                         |  3,267,340 |     |   |  1,485,636 |
| Selling, general and administrative(1